Ispinesib In Combination With Capecitabine In Patients With Solid Tumors
Status:
Completed
Trial end date:
1969-12-31
Target enrollment:
Participant gender:
Summary
The purpose of this study is to determine the dose regimen of Ispinesib in combination with
capecitabine in patients with solid tumors. Ispinesib is dosed by 1-hour intravenous infusion
every 3 weeks and capecitabine is dosed orally, twice a day for 14 days with a 1 week rest
period. A patient may continue to receive treatment as long as they are benefiting from the
treatment. Blood samples will be taken at specific times to measure the amount of both drugs
in your body at specific times after the drug is given. Blood samples will also be taken for
lab tests such as complete blood counts and clinical chemistries. Physical exams will be
performed before each treatment with Ispinesib. During the treatment phase, the patients will
undergo regular assessments for safety and clinical response.